WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Mosunetuzumab, a first-in-class T-cell engaging bispecific antibody targeting CD20 and CD3, has gained accelerated/conditional approval in the U.S. and European Union for treating relapsed/refractory follicular lymphoma in patients who received two or more prior therapies. WHAT QUESTION DID THIS STUDY ADDRESS? How to dose T-cell engagers to optimize efficacy without compromising safety?
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Brendan
Contact Brendan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack